Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View CHRS insider activity ↗

CHRSCoherus Oncology, Inc.

THE LATEST REPORTED YEAR

The company reported a profit.

$168.02M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$42.17MYear ended December 31, 2025
Profit or loss$168.02MYear ended December 31, 2025
Cash from the business-$138.51MYear ended December 31, 2025
Total assets$191.18MAs of June 30, 2026
Total liabilities$130.35MAs of June 30, 2026
Cash & equivalents$82.92MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$0
2018-12
$356.07M
2019-12
$475.82M
2020-12
$326.55M
2021-12
$211.04M
2022-12
$257.24M
2023-12
$26.39M
2024-12
$42.17M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$42,172,000March 9, 202610-K ↗
January 1, 2024 – December 31, 2024$26,389,000March 9, 202610-K ↗
January 1, 2023 – December 31, 2023$257,244,000March 17, 202510-K ↗
January 1, 2022 – December 31, 2022$211,042,000March 17, 202510-K ↗
January 1, 2021 – December 31, 2021$326,551,000March 15, 202410-K ↗
January 1, 2020 – December 31, 2020$475,824,000March 6, 202310-K ↗
January 1, 2019 – December 31, 2019$356,071,000February 23, 202210-K ↗
January 1, 2018 – December 31, 2018$0February 25, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · Retrieved October 14, 2026

Response SHA-256: 5c5765981b2a86ba6afe797bbe14b15cb57f0db8164b0eb431640837c7af90f8

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.